Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14664195 | 1.00 | TRPM8 (0.67) | TRPM8TRPV1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15131619 | 1.00 | TRPM8 (0.67) | TRPM8TRPV1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2628708 | 0.89 | TRPM8 (0.57) | TRPM8TRPV1ALDH1A1 | |
| SCHEMBL6335116 | 0.89 | TRPM8 (0.69) | TRPM8TRPV1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL24540591 | 0.88 | TRPM8 (0.51) | TRPM8TRPV1LMNA | |
| SCHEMBL2628617 | 0.87 | TRPM8 (0.49) | TRPM8TRPV1ALDH1A1NPSR1POLB | |
| SCHEMBL2628712 | 0.87 | TRPM8 (0.50) | TRPM8TRPV1ALDH1A1NPSR1POLB | |
| SCHEMBL24540473 | 0.87 | TRPM8 (0.49) | TRPM8TRPV1ALDH1A1NPSR1POLB | |
| SCHEMBL24540522 | 0.87 | TRPM8 (0.50) | TRPM8ALDH1A1NPSR1POLBKMT2A | |
| SCHEMBL2628667 | 0.87 | TRPM8 (0.50) | TRPM8ALDH1A1NPSR1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 8/4885TRPV1 6/4885ALDH1A1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.